UA72803C2 - A method for the preparation of losartan potassium - Google Patents
A method for the preparation of losartan potassium Download PDFInfo
- Publication number
- UA72803C2 UA72803C2 UA2002119212A UA2002119212A UA72803C2 UA 72803 C2 UA72803 C2 UA 72803C2 UA 2002119212 A UA2002119212 A UA 2002119212A UA 2002119212 A UA2002119212 A UA 2002119212A UA 72803 C2 UA72803 C2 UA 72803C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formula
- potassium
- methanol
- reaction
- differs
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000002083 C09CA01 - Losartan Substances 0.000 title claims abstract description 19
- 229960000519 losartan potassium Drugs 0.000 title claims abstract description 19
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 19
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000012467 final product Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000003586 protic polar solvent Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 12
- -1 2'-(tetrazol-5-yl)-1,1'-biphenyl-4-yl Chemical group 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- FDKIDFYIEWFERB-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;potassium Chemical compound [K].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 FDKIDFYIEWFERB-UHFFFAOYSA-N 0.000 abstract description 2
- WLGIWQDEZIWZQU-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2-trityltetrazol-5-yl)phenyl]phenyl]methyl]-4h-imidazol-5-yl]methanol Chemical compound CCCCC1=NC(Cl)(CO)CN1CC1=CC=C(C=2C(=CC=CC=2)C2=NN(N=N2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 WLGIWQDEZIWZQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 10
- 238000006642 detritylation reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 5
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 150000003536 tetrazoles Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0001618A HU222773B1 (hu) | 2000-04-21 | 2000-04-21 | Eljárás egy ismert tetrazolszármazék előállítására |
| PCT/HU2001/000047 WO2001081336A1 (en) | 2000-04-21 | 2001-04-20 | Process for the synthesis of a known tetrazol derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72803C2 true UA72803C2 (en) | 2005-04-15 |
Family
ID=89978280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002119212A UA72803C2 (en) | 2000-04-21 | 2001-04-20 | A method for the preparation of losartan potassium |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6710183B2 (ru) |
| EP (1) | EP1274702B1 (ru) |
| JP (1) | JP2003531203A (ru) |
| AT (1) | ATE259366T1 (ru) |
| AU (1) | AU2001254998A1 (ru) |
| BG (1) | BG65699B1 (ru) |
| CZ (1) | CZ301029B6 (ru) |
| DE (1) | DE60102008T2 (ru) |
| EA (1) | EA004633B1 (ru) |
| EE (1) | EE05064B1 (ru) |
| ES (1) | ES2215130T3 (ru) |
| HU (1) | HU222773B1 (ru) |
| PL (1) | PL198664B1 (ru) |
| SK (1) | SK286740B6 (ru) |
| TR (1) | TR200401058T4 (ru) |
| UA (1) | UA72803C2 (ru) |
| WO (1) | WO2001081336A1 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK722003A3 (en) * | 2001-05-18 | 2003-12-02 | Aurobindo Pharma Ltd | Process for the crystallization of losartan potassium |
| WO2003093262A2 (en) * | 2002-04-29 | 2003-11-13 | Teva Pharmaceutical Industries Ltd. | Processes for preparing losartan and losartan potassium |
| WO2004039352A2 (en) * | 2002-10-31 | 2004-05-13 | Ranbaxy Laboratories Limited | Amorphous form of losartan potassium |
| AU2003269470A1 (en) * | 2003-04-03 | 2004-10-25 | Ipca Laboratories Limited | A process for the synthesis of losartan potassium |
| US6916935B2 (en) * | 2003-05-06 | 2005-07-12 | Ipca Laboratories | Losartan potassium synthesis |
| US7345071B2 (en) | 2003-05-07 | 2008-03-18 | Ipca Laboratories Limited | Process for the synthesis of Losartan potassium |
| EP1709034A2 (en) * | 2004-01-06 | 2006-10-11 | IPCA Laboratories Limited | An improved process for the synthesis of losartan potassium |
| EP1812423A1 (en) | 2004-11-11 | 2007-08-01 | LEK Pharmaceuticals D.D. | Process for the synthesis of tetrazoles |
| ITTO20060560A1 (it) * | 2006-07-27 | 2008-01-28 | S I M S S R L | Composti intermedi per la preparazione di antagonisti dell¿angiotensina ii |
| SG174089A1 (en) * | 2006-08-22 | 2011-09-29 | Ranbaxy Lab Ltd | Matrix metalloproteinase inhibitors |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US11327065B1 (en) * | 2021-08-27 | 2022-05-10 | Jubilant Generics Limited | Preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| DE4224133A1 (de) * | 1992-07-22 | 1994-01-27 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
| US5206374A (en) * | 1991-11-18 | 1993-04-27 | E. I. Du Pont De Nemours And Company | Process for preparing tetrazolylphenylboronic acid intermediates |
| DE69233734D1 (de) * | 1991-11-18 | 2008-06-26 | Du Pont | 2-(2'-Triphenylmethyl-2'H-tetrazol-5'-yl)phenylborsäure als Zwischenprodukt zur Synthese von A II Receptorenantagonisten |
| JPH09507075A (ja) * | 1993-12-23 | 1997-07-15 | メルク エンド カンパニー インコーポレーテッド | ロサルタンの多形とロサルタン▲ｉｉ▼形調製のための方法 |
| WO1995026188A1 (en) * | 1994-03-29 | 1995-10-05 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
| ES2105939B1 (es) * | 1994-08-02 | 1998-07-01 | Uriach & Cia Sa J | Nuevos pirazoles con actividad antagonista de la angiotensina ii. |
-
2000
- 2000-04-21 HU HU0001618A patent/HU222773B1/hu active IP Right Grant
-
2001
- 2001-04-20 AT AT01928134T patent/ATE259366T1/de not_active IP Right Cessation
- 2001-04-20 UA UA2002119212A patent/UA72803C2/uk unknown
- 2001-04-20 DE DE60102008T patent/DE60102008T2/de not_active Expired - Fee Related
- 2001-04-20 EA EA200201122A patent/EA004633B1/ru not_active IP Right Cessation
- 2001-04-20 JP JP2001578426A patent/JP2003531203A/ja active Pending
- 2001-04-20 PL PL356929A patent/PL198664B1/pl not_active IP Right Cessation
- 2001-04-20 CZ CZ20023000A patent/CZ301029B6/cs not_active IP Right Cessation
- 2001-04-20 ES ES01928134T patent/ES2215130T3/es not_active Expired - Lifetime
- 2001-04-20 WO PCT/HU2001/000047 patent/WO2001081336A1/en active IP Right Grant
- 2001-04-20 SK SK1289-2002A patent/SK286740B6/sk not_active IP Right Cessation
- 2001-04-20 EP EP01928134A patent/EP1274702B1/en not_active Expired - Lifetime
- 2001-04-20 US US10/182,109 patent/US6710183B2/en not_active Expired - Fee Related
- 2001-04-20 EE EEP200200460A patent/EE05064B1/xx not_active IP Right Cessation
- 2001-04-20 TR TR2004/01058T patent/TR200401058T4/xx unknown
- 2001-04-20 AU AU2001254998A patent/AU2001254998A1/en not_active Abandoned
-
2002
- 2002-08-23 BG BG107031A patent/BG65699B1/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001081336A8 (en) | 2002-08-29 |
| CZ301029B6 (cs) | 2009-10-14 |
| AU2001254998A1 (en) | 2001-11-07 |
| EE05064B1 (et) | 2008-08-15 |
| EA200201122A1 (ru) | 2003-04-24 |
| DE60102008D1 (de) | 2004-03-18 |
| WO2001081336A1 (en) | 2001-11-01 |
| EP1274702A1 (en) | 2003-01-15 |
| HU0001618D0 (en) | 2000-06-28 |
| DE60102008T2 (de) | 2004-12-09 |
| BG107031A (en) | 2003-08-29 |
| PL198664B1 (pl) | 2008-07-31 |
| PL356929A1 (en) | 2004-07-12 |
| HU222773B1 (hu) | 2003-10-28 |
| TR200401058T4 (tr) | 2004-06-21 |
| ATE259366T1 (de) | 2004-02-15 |
| JP2003531203A (ja) | 2003-10-21 |
| US6710183B2 (en) | 2004-03-23 |
| US20030078435A1 (en) | 2003-04-24 |
| EA004633B1 (ru) | 2004-06-24 |
| EE200200460A (et) | 2003-12-15 |
| BG65699B1 (bg) | 2009-07-31 |
| ES2215130T3 (es) | 2004-10-01 |
| SK12892002A3 (sk) | 2002-12-03 |
| HUP0001618A2 (hu) | 2002-11-28 |
| SK286740B6 (sk) | 2009-04-06 |
| EP1274702B1 (en) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6371871B2 (ja) | メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル］ピリミジン−５−イル｝メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法 | |
| EP2262756B1 (en) | Process for preparing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrates | |
| UA72803C2 (en) | A method for the preparation of losartan potassium | |
| EP1658281B1 (en) | A method of removing the triphenylmethane protecting group | |
| JP2004520446A (ja) | ロサルタンカリウムの結晶化方法 | |
| WO2012055994A1 (en) | Process for preparing olmesartan medoxomil | |
| EP2036904A1 (en) | A process for the preparation of olmesartan medoxomil | |
| KR20170108080A (ko) | 메데토미딘의 합성에서 유용한 3-아릴부탄알과 같은 화합물의 제조 방법 | |
| RU2425038C2 (ru) | Способ получения 1-[ди(4-цианфенил)метил]-1,2,4-триазола | |
| RU2601749C1 (ru) | Способ получения 4'-фторспиро[циклопропан-1,3'-индол]-2'(1'н)-она | |
| JP4739695B2 (ja) | ５−アミノ―１―置換―１，２，４―トリアゾールの製造方法、及び該製造方法で得られるトリアゾール誘導体 | |
| WO2006097121A1 (en) | Method for producing biphenyl-tetrazole compounds | |
| WO2014174532A2 (en) | An improved process for the preparation of emtricitabine | |
| EP2001869A1 (en) | Process for producing biphenyl-tetrazole compounds | |
| JP2005126434A (ja) | ベンジルイミダゾール誘導体の製造方法 | |
| WO2007062675A1 (en) | Method for producing metal salts of losartan |